iifl-logo-icon 1

Sun Pharmaceuticals Industries Ltd Share Price

1,819
(0.24%)
Dec 24, 2024|03:31:17 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open1,814.9
  • Day's High1,831.75
  • 52 Wk High1,960.35
  • Prev. Close1,814.6
  • Day's Low1,803.15
  • 52 Wk Low 1,239.3
  • Turnover (lac)20,388.69
  • P/E157.92
  • Face Value1
  • Book Value103.34
  • EPS11.49
  • Mkt. Cap (Cr.)4,36,439.03
  • Div. Yield0.74
View All Historical Data
Loading...
  • Open1,606.35
  • Day's High1,677.05
  • Spot1,657.65
  • Prev. Close1,614.95
  • Day's Low1,598.8
  • ViewLong BuildUp
  • Market Lot350
  • OI(Chg %)7,81,550 (18.36%)
  • Roll Over%0.74
  • Roll Cost1.16
  • Traded Vol.36,70,450 (-45.28%)
View More Futures

Sun Pharmaceuticals Industries Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

1,814.9

Prev. Close

1,814.6

Turnover(Lac.)

20,388.69

Day's High

1,831.75

Day's Low

1,803.15

52 Week's High

1,960.35

52 Week's Low

1,239.3

Book Value

103.34

Face Value

1

Mkt Cap (₹ Cr.)

4,36,439.03

P/E

157.92

EPS

11.49

Divi. Yield

0.74

Sun Pharmaceuticals Industries Ltd Corporate Action

19 Jun 2024

12:00 AM

AGM

Announcement Date: 19 Jun, 2024

arrow

22 May 2024

12:00 AM

Dividend

Dividend Amount: 5

Record Date: 12 Jul, 2024

arrow

9 Oct 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

Sun Pharmaceuticals Industries Ltd NEWS AND UPDATE

Sun Pharma reports Q2 net profit at ₹3,040 Crore
29 Oct 2024|10:30 AM

Sun Pharma has bolstered its speciality pipeline with a partnership with Philogen to commercialise late-stage candidate Fibromun.

Read More
Sun Pharma's Hair Loss Drug Approved by USFDA
26 Jul 2024|01:45 PM

The US Food and Drug Administration (USFDA) has approved LEQSELVI (deuruxolitinib) 8 mg tablets, according to a regulatory filing.

Read More
Mayne Pharma Sues Sun Pharma in Patent Dispute
25 Jul 2024|11:57 AM

IMVEXXY is a vaginal insert designed to lessen pain during sexual activity after menopause which is manufactured by Mayne Pharma.

Read More
USFDA grills Sun Pharma for manufacturing issues at Dadra facility
4 Jul 2024|11:24 AM

The warning letter detailed substantial violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals at the facility.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Sun Pharmaceuticals Industries Ltd SHAREHOLDING SNAPSHOT

24 Dec, 2024|11:06 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 54.47%

Foreign: 0.00%

Indian: 54.47%

Non-Promoter- 36.63%

Institutions: 36.62%

Non-Institutions: 8.89%

Custodian: 0.00%

Share Price

Sun Pharmaceuticals Industries Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

239.93

239.93

239.93

239.93

Preference Capital

0

0

0

0

Reserves

23,454.47

23,508.43

24,348.02

26,698.54

Net Worth

23,694.4

23,748.36

24,587.95

26,938.47

Minority Interest

View Balance Sheet
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Revenue

15,585.98

14,116.05

12,531.93

7,923.84

yoy growth (%)

10.41

12.64

58.15

3.12

Raw materials

-5,650.39

-5,107.48

-4,567.72

-3,492.77

As % of sales

36.25

36.18

36.44

44.07

Employee costs

-2,000.78

-1,805.98

-1,702.77

-1,617.69

View Profit & Loss
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Profit before tax

2,127.39

945.13

3,253

430.52

Depreciation

-1,349.95

-1,236.43

-561.56

-432.23

Tax paid

-406.85

-13.17

-41.86

25.39

Working capital

-5,179.41

-888.49

3,200.15

1,619.85

Other operating items

View Cash Flow
Y/e 31 MarMar-2022Mar-2021Mar-2020Mar-2018

Growth matrix (%)

Revenue growth

10.41

12.64

58.15

3.12

Op profit growth

28.82

-16.76

2,104.23

7.94

EBIT growth

107.43

-66.87

347.1

296.01

Net profit growth

-111.86

-73.76

-749.25

2,065.45

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

47,758.45

43,278.87

38,426.42

33,233.08

32,325.17

Excise Duty

0

0

0

0

0

Net Sales

47,758.45

43,278.87

38,426.42

33,233.08

32,325.17

Other Operating Income

738.4

606.81

228.07

265.06

512.33

Other Income

1,354.19

634.52

921.51

835.52

635.98

Sun Pharmaceuticals Industries Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,819

157.924,35,359.33863.290.745,123.6798.33

Divis Laboratories Ltd

DIVISLAB

5,782.35

84.511,55,255.325180.512,302513.62

Mankind Pharma Ltd

MANKIND

2,910.6

59.991,20,250.73634.4302,529.74269.23

Cipla Ltd

CIPLA

1,475.75

28.171,19,240.171,178.160.883,969.86360.73

Torrent Pharmaceuticals Ltd

TORNTPHARM

3,399.45

70.761,15,763.454600.822,376222.38

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Sun Pharmaceuticals Industries Ltd

Management

Register Office

Registrar Office

Chairman & Managing Director

Dilip S Shanghvi

Non-Exec & Non-Independent Dir

Sudhir V Valia

Non-Exec. & Independent Dir.

Gautam Doshi

Lead Independent Director

Pawan Goenka

Independent Director

Rama Bijapurkar

Company Sec. & Compli. Officer

Anoop Deshpande

Independent Director

Sanjay K Asher

Independent Director

Rolf Hoffmann

Whole Time Director

Aalok Shanghvi

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Reports by Sun Pharmaceuticals Industries Ltd

Summary

Sun Pharmaceutical Industries Limited including its subsidiaries and associates (Sun Pharma) is the fourth largest global specialty generic company that is ranked No. 1 in India and No. 8 in the US. It is the largest Indian pharmaceutical company in the US and among the leading Indian pharmaceutical companies in emerging markets. The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, complex or difficult to make technology intensive products, over-the-counter (OTC) products, anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates. The product portfolio of over 2000 high quality molecules covers multiple dosage forms, including tablets, capsules, injectables, sprays, inhalers, drug delivery systems, ointments, creams and liquids. The products cater to a vast range of therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, orthopaedic, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals.The company has global presence with 43 manufacturing facilities across the world. India and the US are two predominant markets, accounting for nearly 70% of the companys revenue. The company has a robust product pipeline and established presence in Europe and high-growth emerging markets like Russia, Romania, South Africa, Brazil a
Read More

Company FAQs

What is the Sun Pharmaceuticals Industries Ltd share price today?

The Sun Pharmaceuticals Industries Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹1819 today.

What is the Market Cap of Sun Pharmaceuticals Industries Ltd?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sun Pharmaceuticals Industries Ltd is ₹436439.03 Cr. as of 24 Dec ‘24

What is the PE and PB ratio of Sun Pharmaceuticals Industries Ltd?

The PE and PB ratios of Sun Pharmaceuticals Industries Ltd is 157.92 and 18.45 as of 24 Dec ‘24

What is the 52 Week High and Low of Sun Pharmaceuticals Industries Ltd?

The 52-week high/low is the highest and lowest price at which a Sun Pharmaceuticals Industries Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Sun Pharmaceuticals Industries Ltd is ₹1239.3 and ₹1960.35 as of 24 Dec ‘24

What is the CAGR of Sun Pharmaceuticals Industries Ltd?

Sun Pharmaceuticals Industries Ltd's CAGR for 5 Years at 33.47%, 3 Years at 31.81%, 1 Year at 45.46%, 6 Month at 21.42%, 3 Month at -2.58% and 1 Month at 0.87%.

What is the shareholding pattern of Sun Pharmaceuticals Industries Ltd?

The shareholding pattern of Sun Pharmaceuticals Industries Ltd is as follows:
Promoters - 54.48 %
Institutions - 36.63 %
Public - 8.89 %

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2024, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp